Obesity in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 68 geographical markets and provides an Excel-based forecast model for the obesity market through 2031.
Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031.
The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
Scope
This publication is an expanded version of the Excel model containing the patient-based forecast sales for obesity, covered in GlobalData’s report “Obesity: Seven -Market Drug Forecast and Market Analysis Update”, published in January 2025. In addition to patient based forecast sales data for the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), this report contains sales forecast extrapolations for an additional 61 geographical markets (61M), totaling 68 markets (68M).
Key Highlights
Report deliverables include a Word report and an Excel-based forecast model.
Forecast includes the 7 major markets (7MM).
Forecast covers the period 2021-2031.
- Growth in the obesity market will be driven by the launch of 13 new pipeline products, including Novo Nordisk’s Wegovy (semaglutide), CagriSema (semaglutide + cagrilintide), and oral semaglutide (NN-9932), Eli Lilly’s tirzepatide, retatrutide, and orforglipron, Versanis Bio’s bimagrumab (BYM338), and Pfizer’s PF-07081532 and danuglipron tromethamine.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM obesity therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Eli Lilly
Boehringer Ingelheim
Zealand Pharma
Amgen
Structure Therapeutics
Viking Therapeutics
Veru Inc
Altimmune
Metsera
Rose Pharma
Empros Pharma
Lipocine Inc
Glyscend Inc
Rhythm Pharmaceuticals
Roche
H2-Pharma
Chelapharm
Vivus Inc.
Orexigen Therapeutics
Currax Pharmaceuticals
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Obesity reports